Edgewise Therapeutics to Present on Sevasemten for Becker Muscular Dystrophy at the 29th International Annual Congress of the World Muscle Society
EWTX Stock | USD 26.26 0.46 1.72% |
Slightly above 66% of Edgewise Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Edgewise Therapeutics suggests that many traders are alarmed. Edgewise Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Edgewise Therapeutics' earnings reports, geopolitical events, and overall market trends.
Edgewise |
Edgewise Therapeutics, Inc., , a leading muscle disease biopharmaceutical company, today announced its participation at the 29th Interna
Read at businesswire.com
Edgewise Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Edgewise Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Edgewise Therapeutics Maximum Pain Price Across March 21st 2025 Option Contracts
Edgewise Therapeutics' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Edgewise Therapeutics close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Edgewise Therapeutics' options.
Edgewise Therapeutics Fundamental Analysis
We analyze Edgewise Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Edgewise Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Edgewise Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Outstanding
Shares Outstanding Comparative Analysis
Edgewise Therapeutics is currently under evaluation in shares outstanding category among its peers. Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Edgewise Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Edgewise Therapeutics stock to make a market-neutral strategy. Peer analysis of Edgewise Therapeutics could also be used in its relative valuation, which is a method of valuing Edgewise Therapeutics by comparing valuation metrics with similar companies.
Peers
Edgewise Therapeutics Related Equities
DSGN | Design Therapeutics | 6.75 | ||||
XLO | Xilio Development | 5.56 | ||||
CCCC | C4 Therapeutics | 2.07 | ||||
CGEM | Cullinan Oncology | 1.18 | ||||
RVMD | Revolution Medicines | 0.98 | ||||
PASG | Passage Bio | 0 | ||||
IPSC | Century Therapeutics | 0.11 | ||||
ACET | Adicet Bio | 0.22 | ||||
BDTX | Black Diamond | 0.45 | ||||
IKNA | Ikena Oncology | 0.66 | ||||
HOWL | Werewolf Therapeutics | 0.75 | ||||
VOR | Vor Biopharma | 2.21 | ||||
MLYS | Mineralys Therapeutics, | 2.74 | ||||
CELC | Celcuity LLC | 2.84 |
Additional Tools for Edgewise Stock Analysis
When running Edgewise Therapeutics' price analysis, check to measure Edgewise Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edgewise Therapeutics is operating at the current time. Most of Edgewise Therapeutics' value examination focuses on studying past and present price action to predict the probability of Edgewise Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edgewise Therapeutics' price. Additionally, you may evaluate how the addition of Edgewise Therapeutics to your portfolios can decrease your overall portfolio volatility.